Livalo and Sofosbuvir, velpatasvir, and voxilaprevir

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Voxilaprevir may significantly increase the blood levels of pitavastatin. This can increase the risk of side effects such as liver damage and a rare but serious condition called rhabdomyolysis that involves the breakdown of skeletal muscle tissue. In some cases, rhabdomyolysis can cause kidney damage and even death. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need to stop taking pitavastatin while you are being treated with voxilaprevir. Let your doctor know immediately if you have unexplained muscle pain, tenderness, or weakness during treatment with pitavastatin or similar medications, especially if these symptoms are accompanied by fever or dark colored urine. You should also seek immediate medical attention if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with sofosbuvir/velpatasvir/voxilaprevir may significantly increase the plasma concentrations of pitavastatin. The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1- and 1B3-mediated hepatic uptake of pitavastatin by velpatasvir and voxilaprevir. Although the interaction has not been studied specifically with pitavastatin, it has been reported with other statins that are also substrates of OATP1B1 and 1B3. High levels of HMG-CoA reductase inhibitory activity in plasma may be associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.

MANAGEMENT: Concomitant use of pitavastatin with sofosbuvir/velpatasvir/voxilaprevir is not recommended.

Livalo

Generic Name: pitavastatin

Brand name: Livalo, Zypitamag

Synonyms: n.a.

What is Livalo?

Sofosbuvir, velpatasvir, and voxilaprevir

Generic Name: sofosbuvir / velpatasvir / voxilaprevir

Brand name: Vosevi

Synonyms: Sofosbuvir, Velpatasvir, and Voxilaprevir

What is Sofosbuvir, velpatasvir, and voxilaprevir?